Metal-Complexes Bearing Releasable CO Differently Modulate Amyloid Aggregation.
Sara La MannaValentina RovielloFabiana NapolitanoAnna Maria MalfitanoVittoria MonacoAntonello MerlinoMaria MontiKonrad KowalskiŁukasz SzczupakDaniela MarascoPublished in: Inorganic chemistry (2023)
Neurodegenerative diseases are often associated with an uncontrolled amyloid aggregation. Hence, many studies are oriented to discover new compounds that are able to modulate self-recognition mechanisms of proteins involved in the development of these pathologies. Herein, three metal-complexes able to release carbon monoxide (CORMs) were analyzed for their ability to affect the self-aggregation of the amyloidogenic fragment of nucleophosmin 1, corresponding to the second helix of the three-helix bundle located in the C-terminal domain of the protein, i.e., NPM1 264-277 , peptide. These complexes were two cymantrenes coordinated to the nucleobase adenine ( Cym-Ade ) and to the antibiotic ciprofloxacin ( Cym-Cipro ) and a Re(I)-compound containing 1,10-phenanthroline and 3-CCCH 2 NHCOCH 2 CH 2 -6-bromo-chromone as ligands ( Re-Flavo ). Thioflavin T (ThT) assay, UV-vis absorption and fluorescence spectroscopies, scanning electron microscopy (SEM), and electrospray ionization mass spectrometry (ESI-MS) indicated that the three compounds have different effects on the peptide aggregation. Cym-Ade and Cym-Cipro act as aggregating agents. Cym-Ade induces the formation of NPM1 264-277 fibers longer and stiffer than that formed by NPM1 264-277 alone; irradiation of complexes speeds the formation of fibers that are more flexible and thicker than those found without irradiation. Cym-Cipro induces the formation of longer fibers, although slightly thinner in diameter. Conversely, Re-Flavo acts as an antiaggregating agent. Overall, these results indicate that metal-based CORMs with diverse structural features can have a different effect on the formation of amyloid fibers. A proper choice of ligands attached to metal can allow the development of metal-based drugs with potential application as antiamyloidogenic agents.